Exploration of Spirocyclic Derivatives of Ciprofloxacin as Antibacterial Agents
Open Access
Abstract
The previously reported as well as newly synthesized derivatives of the 1-oxa-9-azaspiro[5.5]undecane were employed in the synthesis of thirty-six derivatives of ciprofloxacin using commercially available 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and the literature protocol involving the preparation of boron chelate complex to facilitate nucleophilic aromatic substitution. All new fluoroquinolone derivatives were tested against two gram-positive as well as three gram-negative strains of bacteria. With the activity spectrum of the new derivatives being substantially narrower than that of ciprofloxacin, compounds were distinctly active against two of the five strains: gram-negative Acinetobacter baumannii 987® and gram-positive Bacillus cereus 138®. Towards these two strains, a large group of compounds displayed equal or higher potency than ciprofloxacin.Keywords
Funding Information
- Russian Foundation for Basic Research (# 21-53-12001)
This publication has 24 references indexed in Scilit:
- Synthesis and biological evaluation of levofloxacin core-based derivatives with potent antibacterial activity against resistant Gram-positive pathogensBioorganic & Medicinal Chemistry Letters, 2015
- The use of spirocyclic scaffolds in drug discoveryBioorganic & Medicinal Chemistry Letters, 2014
- Scaffold Flatness: Reversing the TrendSpringer Science Reviews, 2013
- Front‐Loading Natural‐Product‐Screening Libraries for log P: Background, Development, and ImplementationChemistry & Biodiversity, 2013
- Privileged scaffolds for library design and drug discoveryCurrent Opinion in Chemical Biology, 2010
- Synthesis and In Vitro Antibacterial Activity of 7‐(3‐Alkoxyimino‐4‐methyl‐4‐methylaminopiperidin‐1‐yl)‐fluoroquinolone DerivativesArchiv der Pharmazie, 2010
- Developability assessment in pharmaceutical industry: An integrated group approach for selecting developable candidatesJournal of Pharmaceutical Sciences, 2009
- Requirements for a lead compound to become a clinical candidateBMC Neuroscience, 2008
- Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substancesNature Protocols, 2008
- Boron Complex of a Member of the Quinolone FamilyActa Crystallographica Section C Crystal Structure Communications, 1997